PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 660.00K | 506.00K | 444.00K | 708.00K | 764.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 660.00K | 506.00K | 444.00K | 708.00K | 764.00K |
| Cost of Revenue | 291.00K | 237.00K | 206.00K | 258.00K | 296.00K |
| Gross Profit | 369.00K | 269.00K | 238.00K | 450.00K | 468.00K |
| SG&A Expenses | 779.00K | 708.00K | 847.00K | 743.00K | 731.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.16M | 1.02M | 1.13M | 1.09M | 1.10M |
| Operating Income | -503.00K | -518.00K | -683.00K | -379.00K | -336.00K |
| Income Before Tax | -610.00K | -624.00K | -785.00K | -464.00K | -332.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -610.00K | -624.00K | -785.00K | -464.00K | -332.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -610.00K | -624.00K | -785.00K | -464.00K | -332.00K |
| EBIT | -503.00K | -518.00K | -683.00K | -379.00K | -336.00K |
| EBITDA | -502.00K | -518.00K | -682.00K | -378.00K | -336.00K |
| EPS Basic | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 131.20M | 110.83M | 111.89M | 111.89M | 111.88M |
| Average Diluted Shares Outstanding | 131.20M | 110.83M | 111.89M | 111.89M | 111.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |